XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance

Xeris Biopharma Holdings Inc (NASDAQ:XERS) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction in pre-market trading. The company posted revenue of $71.5 million, a 48.8% year-over-year increase, surpassing the consensus estimate of $65.9 million. Earnings per share (EPS) came in at -$0.01, significantly better than the anticipated -$0.0281.

Key Financial Highlights vs. Estimates

• Revenue Beat: Actual Q2 revenue of $71.5M vs. $65.9M estimate (+8.6% beat)
• EPS Surprise: Reported -$0.01 vs. estimated -$0.0281 (64% better than expected)
• Net Loss Improvement: Net loss narrowed to $1.9M from $15.0M in Q2 2024
• Adjusted EBITDA: $12.5M, up from -$0.4M in the prior-year period

Market Reaction

The stock surged 12.2% in pre-market trading, reflecting investor optimism around the strong revenue growth and improved profitability. The company’s upward revision of its full-year revenue guidance to $280–$290 million (from prior estimates) further bolstered confidence.

Business Performance Drivers

• Recorlev®: Sales surged 136% YoY to $31.4M, driven by increased patient demand.
• Gvoke®: Revenue grew 17% YoY to $23.5M, supported by higher prescriptions and favorable pricing.
• Keveyis®: Sales declined 13% YoY to $11.5M due to reduced shipments.
• Pipeline Progress: XP-8121, a Phase 3-ready subcutaneous levothyroxine candidate, remains a key long-term growth driver.

Strategic Outlook

Management raised its full-year revenue forecast and outlined an ambitious long-term target of $750M in total revenue by 2030, with Recorlev expected to approach $1B in peak net revenue by 2035. The company also highlighted XP-8121’s potential peak revenue of $1–$3 billion.

Upcoming Investor Engagements

Xeris will participate in several healthcare conferences in September, including:

• Cantor Fitzgerald Global Healthcare Conference (Sept. 3)
• Wells Fargo Global Healthcare Conference (Sept. 4)
• H.C. Wainwright Global Investment Conference (Sept. 9)

Conclusion

Xeris’ Q2 results demonstrate accelerating commercial execution, with Recorlev leading growth and profitability improving faster than expected. The raised guidance and strong pipeline prospects suggest sustained momentum.

For more detailed earnings estimates and historical performance, visit Xeris Biopharma’s earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research before making decisions.